… receptor (EGFR) gene mutations [3]. Currently, various EGFR tyrosine kinase inhibitors (EGFR-TKIs)
are standard treatment options for patients with activating EGFR gene mutations. …

… receptor (EGFR) gene mutations are a positive predictive factor for EGFR tyrosine kinase
inhibitors (TKIs). … antibody, but clinical applications have yet to confirm them [89,206,207,208]. …

… The EGFR tyrosine kinase inhibitors (TKIs) gefitinib or erlotinib attain a response rate of
70% and progression-free survival of 9–13 months, although there are subgroups of patients …

… that bind the tyrosine kinase domain of EGFR specifically and … clinical application. For
instance, erlotinib and gefitinib (small molecular EGFR-TKIs) are used to treat patients with EGFR-…

… -targeted cancer therapeutics include monoclonal antibodies (mAbs), which bind to the
extracellular domain of EGFR, and tyrosine kinase inhibitors (TKIs), which mostly target the …

… On the basis of the additive effects of combining a TKI and an EGFR mAb, a phase I study …
The results obtained in the clinical studies with the different agents that target EGFR and …

… The clinical response, however, varies … EGFR-TKIs responsiveness. In order to better
understand the predictive value of these biomarkers and their significance in clinical application we …

… The IPASS (Iressa Pan-Asia Study) [15] was regarded as the milestone for the clinical
application of EGFR TKI, because it was the first randomized clinical trial to compare EGFR-TKI …

… AZD9291 is a potent, selective, irreversible EGFR TKI, effective against the EGFR TKI
sensitizing and resistance T790M mutations. Recently, updated and very promising results of …

… Regarding the clinical application of ctDNA, another … EGFR mutation test has a good ability
to predict EGFR-TKI-treatment efficacy, and it may be a reliable approach to guide EGFR-TKI …